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DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES CHRONIC
HEPATITIS B TREATMENT OUTCOMES IN TURKEY?
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OBJECTIVES: To quantify patient and physician preferences for therapeutic
tradeoffs involving efficacy, side-effect risks, and evidence uncertainty in chronic
hepatitis B (CHB) treatments. METHODS: Physicians who treat CHB patients and
adult patients with a self-reported physician diagnosis of CHB completed a web-
enabled, discrete-choice experiment survey in Turkey. Both patients and physi-
cians answered 12 treatment-choice questions. Each question required evaluating
a pair of hypothetical CHB medication profiles defined by years the medicine has
been studied, probability that patient’s viral load remains undetectable for five
years with possible reversal of disease progression, five-year treatment-related
risks of a fracture and renal insufficiency, and monthly medication cost. Nested-
logit and random-parameters logit models were used to estimate preference
weights for all attribute levels and the mean relative importance of each attribute.
RESULTS: One hundred fifty-nine physicians and 117 patients completed the sur-
vey in Turkey. Turkish physicians and patients disagreed on the relative impor-
tance of all treatment attributes. Turkish patients ranked years of evidence as the
most important attribute, while Turkish physicians ranked risk of renal insuffi-
ciency as most important. Turkish physicians were willing to accept a 3.2% smaller
increase in fracture risk than patients for an additional year of evidence.
CONCLUSIONS: This is the first study to quantify patient and physician prefer-
ences for CHB treatment attributes and the first study to elicit physician and pa-
tient preferences for years of evidence. We observe different discrepancies be-
tween physician and patient preferences in Turkey. Such discrepancies may
interfere with optimal outcomes if not considered in patient-physician interac-
tions.
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OBJECTIVES: In order to make HIV treatment as effective as possible expert judge-
ment and patient preferences should be attuned. This study aims to elicit patients’
preferences and to compare them to physicians’ assumptions in HIV therapy.
METHODS: In the first part qualitative and quantitative methods were applied to
identify patient preferences. Literature review, focus groups, direct assessment
and a discrete choice experiment were conducted to elicit relevant treatment ob-
jectives from the patients= perspective. In the second part an expert survey with
German physicians (HIV specialists) was used to assess the experts= judgement for
the same objectives. The discrete choice experiment was conducted using a frac-
tional factorial design (two-fold, six attributes) and the statistical data analysis
used random effect logit models. RESULTS: A total of 218 patients and 131 physi-
cians participated in the study. “Emotional quality of life: HIV- infection not obvi-
ous“ was ranked highest both by physicians and patients (coeff. phys.: 4.00, coeff.
pat.: 2.98) followed by “social quality of life: possibility to take part in social life”
(phys.: 1.95, pat.: 1.14) as well as “constitution: less diarrhoea, and nausea” (phys.:
1.93, pat.: 1.61), the latter on second rank for the patients. Less important and
ranking of posts four to six were “life span: maximal increase” (phys.: 0.85, pat.:
0.74), “avoidance of long-term impairment” (phys.: 0.83, pat.: 0.41) and “flexibility
and dosage: treatment-combination of max. 3 tablets per day” (phys.: 0.64, pat.:
0.45). All six attributes had significant effects in both models. CONCLUSIONS: This
enables testing of the concordance between patient and physician valuation of
multiple treatment goals for HIV/AIDS therapy. Experts’ assumptions and patients’
preferences were similar, showing that physicians in HIV treatment are aware of
their patients’ needs and wishes. DCE and direct assessment proved to be valid
instruments to elicit treatment preferences in HIV treatment for experts as well as
for patients.
PIN91
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OBJECTIVES: To investigate whether patient reported outcomes could detect dif-
ferences between H1N1 and seasonal influenza vaccinations on adverse events
over a 26 week follow up period.METHODS: In this evaluation, PROBE methodology
consisting of a web-based system supplemented by telephone reporting was used
to collect naturalistic data from people who had received an influenza vaccination
during 2009-2010 season. People were recruited through media advertising and
awareness campaigns in public places and work (West of Scotland). Data collection
on day of immunisation, after 3 days, 8 days, 6 weeks, 12 weeks and 26 weeks. Data
included age, sex, presence or absence of chronic illness, flu vaccination history,
any side effects following vaccination including the duration and action taken.
RESULTS: A total of 1103 vaccine recipients including 134 young children ( 5
years) participated; 694 (63%) received H1N1 vaccine only, 135 (12%) seasonal only,
224 (20%) both H1N1 and seasonal vaccines and 50 (5%) received H1N1 or seasonal
vaccine with a non-influenza vaccine (e.g. travel or pneumococcal). Overall, 70% of
respondents reported experiencing a side effect after vaccination – this includes
pain/discomfort at the injection site and any other side effects. Of the 964 recipi-
ents of an H1N1 vaccine, significantly more (511, 74%) experienced a side effect
compared with those who received only the seasonal flu vaccine (45%, 2-test p
0.001). Multivariate regression analysis revealed that female sex and the H1N1
vaccination were more likely to report any side effect (OR 2.10, p0.001 and OR 4.47,
p0.001 respectively) and age  70 less likely to report (OR 0.29, p0.001).
CONCLUSIONS: People receiving the H1N1 vaccination were more likely to experi-
ence side effects than seasonal influenza vaccination alone. This evaluation shows
that the PROBE methodology quickly and simply captured patient reported out-
come information in a vaccinated population including children.
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OBJECTIVES: Primary analysis of REPEAT study showed that 72 weeks treatment
with PegIFN-alfa2a/ribavirin was more effective than 48 weeks in chronic hepatitis
C patients non-responders to previous PegIFN-alfa2b/ribavirin. The aim of this
prospectively planned secondary analysis was to assess patient reported outcomes
(PRO) of re-treatment with PegIFN-alfa2a/ribavirin versus previous treatment with
PegIFN-alfa2b/ribavirin in Spain. METHODS: In REPEAT, 950 non-responders to
PegIFN-alfa2b were randomized to PegIFN-alfa2a 360g/week for 12 weeks, then
180g/week for a further 60 or 36 weeks (Arms A or B, respectively), or PegIFN-
alfa2a 180g/week for 72 or 48 weeks (Arms C or D, respectively); all patients re-
ceived ribavirin 1000-1200mg/day. In this sub-analysis, 100 Spanish patients from
10 centres (Arms A: n40; B: n19; C: n11; D: n30) were administered a two-part
questionnaire: part one was completed at baseline (questions on previous PegIFN-
alfa2b/ribavirin therapy) and part two was completed at end of treatment (ques-
tions on recent PegIFN-alfa2a/ribavirin therapy). The questionnaire included 15
items concerning patient perception of viral load, tolerability of treatment, health
status, management of devices as well as side effects and problems experienced
specifically to one treatment. RESULTS: At baseline, 16% patients reported feeling
good/excellent, 43% fair and 41% poor while receiving PegIFN-alfa2b/ribavirin ver-
sus 30%, 49% and 20%, respectively, at end of re-treatment. Significantly more
patients perceived PegIFN-alfa2a/ribavirin to be associated with better/much bet-
ter effects on viral load, tolerance, health status and handling of devices versus
PegIFN-alfa2b/ribavirin. Problems exclusive to PegIFN-alfa2b/ribavirin were re-
ported in 33% of patients while 17% reported new problems with PegIFN-alfa2a/
ribavirin. With either treatment, 96% of patients reported side effects. Patient-
reported tolerance to PegIFN-alfa2a/ribavirin was similar in all treatment arms,
irrespective of dose (p0.069). CONCLUSIONS: Re-treatment with PegIFN-alfa2a/
ribavirin in Spanish patients improved assessed patient reported outcomes versus
previous treatment with PegIFN-alfa2b/ribavirin. Patients reported good tolerance
even in 72 weeks re-treatment.
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OBJECTIVES: To evaluate knowledge and awareness of hepatitis B in general pop-
ulation of Quetta, Pakistan.METHODS:A questionnaire-based cross sectional anal-
ysis was designed. A pre-tested and validated questionnaire containing 20 ques-
tions (6 questions for general information, 4 for symptoms, 6 for transmission and
4 for treatment) was used for data abstraction. Stratified groups from 2 towns of the
city aging 18 years and above were approached. Descriptive statistics were used to
describe demographic of the population. Percentages and frequencies were used to
categorize categorical variables, while means and standard deviations were calcu-
lated for the continuous variables. Non parametric tests (Mann-Whitney and
Kruskal Wallis Test) were used where appropriate. Knowledge scored was catego-
rized into good, medium and poor knowledge. All analyses were performed using
SPSS 16.0. RESULTS: Three hundred and ninety individuals were enrolled in the
study with 210 (53.8%) of males. Majority (n178, 45.6%) were categorized in age
group of 18-30 years. The mean knowledge score was calculated as 8.672.730 (out
of 20) and was categorized as poor. Education level, occupation, income level and
locality had significant relation with knowledge scores of the general population
regarding hepatitis B. CONCLUSIONS: This study shows that there is poor level of
knowledge and awareness of hepatitis B in general population of the city. Disease
specific educational and awareness interventional program is recommended.
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OBJECTIVES: To evaluate HRQoL in hepatitis B patients attending public hospitals
in Quetta, Pakistan.METHODS:A descriptive study was shaped as a questionnaire-
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